The Medical Letter on Drugs and Therapeutics
FROM
ISSUE1174
ISSUE1174
January 19, 2004
Efalizumab (Raptiva) for Treatment of Psoriasis - Two Corrections
Med Lett Drugs Ther. 2004 Jan 19;46(1174):7-8
Disclosures
Objective(s)
SUMMARY: Two Corrections: In the issue of December 8, 2003, volume 45, on page 97 in the table, infliximab (Remicade) is given at weeks 0, 2 and 6 (not days). On page 98, patients in the Leonardi study were treated with etanercept 50 mg twice a week, not once.
© The Medical Letter, Inc. All Rights Reserved.
The Medical Letter, Inc. does not warrant that all the material in this publication is accurate and
complete in every respect. The Medical Letter, Inc. and its editors shall not be held responsible for any
damage resulting from any error, inaccuracy, or omission.
This article has been freely provided.
Previous article